FDA grants priority review to Merck's WINREVAIR for treating pulmonary arterial hypertension, positive.

Merck & Co., Inc. (NYSE:MRK) announced FDA acceptance and priority review for its supplemental Biologics License Application for WINREVAIR, previously approved in 2024 for treating pulmonary arterial hypertension. The Phase 3 ZENITH trial showed a 76% reduction in the risk of major morbidity and mortality events, with a target action date of October 25, 2025.

Merck & Co., Inc. (NYSE:MRK) operates through Pharmaceutical and Animal Health Segments. While MRK is a solid investment, certain AI stocks may offer greater upside potential. A free report on the best short-term AI stock is available for those seeking opportunities in the market.

For more insights on stock investments, check out “The Best and Worst Dow Stocks for the Next 12 Months” and “10 Unstoppable Stocks That Could Double Your Money.” None of the information provided contains promotional or marketing language.

Read more at Yahoo Finance: FDA Grants Priority Review for Merck & Co’s (MRK) WINREVAIR